Editas Q2 2020 Earnings Report
Key Takeaways
Editas Medicine reported its Q2 2020 results, highlighting the regaining of full control of ocular medicines, progress in clinical trials for EDIT-101, plans to file IND for EDIT-301, and a strengthened balance sheet through an equity offering. The company's cash, cash equivalents, and marketable securities totaled $599 million.
Regained full control of ocular medicines under new agreement with AbbVie.
BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020.
Plan to file IND for EDIT-301 for sickle cell disease by end of 2020.
Strengthened balance sheet through equity offering raising $216 million in gross proceeds.
Editas
Editas
Forward Guidance
Editas Medicine expects its existing cash, cash equivalents and marketable securities of $598.7 million at June 30, 2020, and anticipated interest income will enable it to fund its operating expenses and capital expenditures into 2023.